Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection

[1]  D. S. Hage,et al.  Characterization of drug interactions with serum proteins by using high-performance affinity chromatography. , 2011, Current drug metabolism.

[2]  Jeong-Yoon Kim,et al.  Role of the RAM network in cell polarity and hyphal morphogenesis in Candida albicans. , 2008, Molecular biology of the cell.

[3]  C. Lass‐Flörl,et al.  Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing , 2008, Antimicrobial Agents and Chemotherapy.

[4]  A. Yamada,et al.  Use of a serum‐based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds , 2008, Microbiology and immunology.

[5]  F. Ikeda,et al.  Direct Comparison of the Pharmacodynamics of Four Antifungal Drugs in a Mouse Model of Disseminated Candidiasis Using Microbiological Assays of Serum Drug Concentrations , 2007, Microbiology and immunology.

[6]  K. Garey,et al.  Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia , 2006, Antimicrobial Agents and Chemotherapy.

[7]  J. Lopez-Ribot,et al.  Inhibition of Filamentation Can Be Used To Treat Disseminated Candidiasis , 2006, Antimicrobial Agents and Chemotherapy.

[8]  A. Yamada,et al.  Determination of Antifungal Activities in Serum Samples from Mice Treated with Different Antifungal Drugs Allows Detection of an Active Metabolite of Itraconazole , 2006, Microbiology and immunology.

[9]  D. Snydman,et al.  Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia , 2005, Antimicrobial Agents and Chemotherapy.

[10]  D. Loebenberg,et al.  Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis , 2004, Antimicrobial Agents and Chemotherapy.

[11]  J. Lopez-Ribot,et al.  Engineered Control of Cell Morphology In Vivo Reveals Distinct Roles for Yeast and Filamentous Forms of Candida albicans during Infection , 2003, Eukaryotic Cell.

[12]  D. Andes,et al.  In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[13]  D. Andes.  In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis , 2003, Antimicrobial Agents and Chemotherapy.

[14]  D. Andes,et al.  In Vivo Pharmacodynamics of a New Triazole, Ravuconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[15]  J. Karlowsky,et al.  Influence of Human Serum on Antifungal Pharmacodynamics with Candida albicans , 2001, Antimicrobial Agents and Chemotherapy.

[16]  L. See,et al.  Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe CandidaInfections Treated with Fluconazole , 2000, Antimicrobial Agents and Chemotherapy.

[17]  M. Klepser,et al.  Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans andCryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.

[18]  D. Andes,et al.  Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model , 1999, Antimicrobial Agents and Chemotherapy.

[19]  Michael H. Miller,et al.  Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.

[20]  Ronald N. Jones,et al.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans , 1997, Antimicrobial agents and chemotherapy.

[21]  J. Prieto,et al.  Activity of fluconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. , 1994, The Journal of antimicrobial chemotherapy.

[22]  M. Saag,et al.  Azole antifungal agents: emphasis on new triazoles , 1988, Antimicrobial Agents and Chemotherapy.

[23]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.

[24]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[25]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.

[26]  F. del Moral,et al.  Activity of voriconazole: post-antifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. , 1999, Scandinavian journal of infectious diseases.